BioNTech (Biopharmaceutical New Technologie) AG is a spin-out of the Johannes Gutenberg-University, Mainz. The company is a holding with 7 subsidiary biotech companies operating under its roof that all aim to develop innovative diagnostics and therapeutics to enhance the therapy of cancer and life-threatening diseases. BioNTech AG has exclusive access to molecular markers that form the rational base to design personalized approaches for immune interventions.
Ribological GmbH is a BioNTech subsidiary operating in Mainz, Germany. Ribological focuses on the discovery, development, and commercialization of innovative cancer immunotherapy therapies based on proprietary RNA-technology. In 2012 Ribological will initiate a phase I therapeutic vaccine clinical trial in patient with malignant melanoma. Projects targeting breast cancer and other solid tumor indications are in the pipeline.